Infection with Ebola (EBO) virus, subtype Zaire (EBO-Z), ity of the virus. Another report of histologic changes associated with increasing virulence during sequential passage in outbred produces severe or fatal illness in nonhuman primates, guinea pigs, and suckling mice [1] . The virus causes lethal hemorguinea pigs found that the virus was fatal for some animals after 3 passages, and its lethality increased through 4 additional rhagic fever in rhesus and cynomolgus macaques (Macaca rhesus and Macaca fascicularis), African green monkeys (Cercopassages [12] . In passages 1 -3, viral replication was observed only in small numbers of MPS cells, including Kupffer's cells pithecus aethiops), and baboons (Papio hamadryas) [2 -5] . It replicates to high titers in the liver, spleen, lymph nodes, and of the liver. Virus titers in the tissues were very low. Beginning with the fourth passage, there was increasing infection of MPS other organs, causing tissue necrosis, hemorrhage, and shock [6 -8] . Cells of the mononuclear phagocytic system (MPS) are cells, hepatocytes, and endothelial cells. Intraperitoneal (ip) or intracerebral (ic) inoculation of EBOmajor targets of infection [8] . Hepatocytes, endothelial cells, and other cell types are also infected.
Z causes lethal infection in newborn mice [13, 14] . Smaller quantities of virus can be detected by titration in newborn mice Guinea pigs inoculated with infectious material from human EBO-Z cases develop a nonlethal febrile illness [9, 10] . Sethan by plaquing in tissue culture: Ryabchikova et al. [10] reported that a 0.1-pfu ic dose of EBO-Z was lethal for 50% quential passage from animal to animal of virus in splenic homogenates results in a progressive increase in virulence, of mice. Only very young suckling mice are sensitive to EBO infection [14] . However, EBO-Z was also lethal for adult SCID soon reaching uniform lethality [3] . Connolly et al. [11] (this supplement) recently provided quantitative data on the adapta-BALB/c mice, in which the virus replicated to high titers in liver, spleen, and other tissues (Huggins J, unpublished data). tion process: They compared the level of viremia induced by non-adapted EBO-Z in strain 13 guinea pigs with that produced EBO infection in SCID mice followed a very different course from that in the above-mentioned animals: While monkeys, by virus from each of 4 sequential passages. The mean serum virus titer 7 days after infection increased from 10 1.2 to 10 5.2 guinea pigs, and suckling mice became acutely ill 4 -6 days after inoculation of EBO-Z and died 6 -11 days after infection, pfu/mL, paralleling an increase from 20% to 100% in the lethal-SCID mice developed gradual, progressive weight loss and slowing of activity and died 20 -25 days after challenge. There are no approved EBO vaccines and no therapeutic [15] ) and the 1995 strain of EBO-Z virus (passed twice in Vero cells) were provided by Peter Jahrling was determined by diluting EBO-Z virus in growth medium and inoculating it ip, sc, or ic in suckling mice or ip, sc, intradermally (USAMRIID). The viruses were amplified in Vero E6 cells, and the supernatant was collected to produce stocks of EBO-Z '76 (id), or intramuscularly (im) in adult mice. The LD 50 dose of mouse-adapted EBO-Z '76 Mp3 Vp2 Mp9 GH inoculated ip into Vp2, EBO-Z '76 Mp3 Vp2, and EBO-Z '95 Vp3. The E6 line of Vero African green monkey kidney cells (Vero C1008, ATCC adult BALB/c mice was determined by inoculating groups of 6-10 mice with serial 10-fold dilutions of virus in 3 separate experi-CRL 1586) was propagated in modified Eagle medium (MEM) with Earle's balanced salts, nonessential amino acids, 10% fetal ments and analyzing the combined results by use of a linear regression program (SPSS, Chicago). In one experiment, groups of 16-bovine serum (FBS), glutamine, penicillin, and streptomycin; the same medium with 2% FBS was used as replacement medium week-old mice were anesthetized and exsanguinated at daily intervals after ip infection with 100 pfu of mouse-adapted virus, the after cells were infected.
Titration by plaquing and by electron microscopy (EM). Virus serum was collected, and the livers and spleens were removed aseptically. The virus titers of the serum and of a weighed portion stocks were serially diluted in MEM, adsorbed onto confluent Vero E6 cells in 12-well dishes, incubated for 1 h at 37ЊC, and covered of each organ were determined as described above, and the remainder was preserved for microscopy study. In another experiment, with an agarose overlay [16] . A 1:5000 dilution of neutral red in buffered saline solution was added 6 days later, and plaques were the same procedure was performed 4 days after ip inoculation of 100 pfu of EBO-Z '76 Vp2, EBO-Z '76 Mp3 Vp2, or mousecounted the following day. EBO virions were also directly enumerated by EM [17] . Virus preparations were mixed with a suspension adapted virus EBO-Z '76 Mp3 Vp2 Mp9 GH. Histology, immunohistochemistry, and EM. Portions of liver of 200-nm polystyrene spheres (Duke Scientific, Palo Alto, CA) at a final concentration of 2.15 1 10 8 spheres/mL. Aliquots (5 mL) and spleen were immersion-fixed for 30 days in 10% neutralbuffered formalin and then embedded in paraffin. Sections were of the virus-sphere mixture were applied to 300-mesh nickel grids, which were precoated with formvar and carbon, and glow-dismounted on glass slides and stained with hematoxylin and eosin; replicate sections were stained immunohistochemically. In brief, charged. After drying, the grids were immersed sequentially in 1% glutaraldehyde in PBS, PBS alone, osmium tetroxide, and distilled sections were treated with a 0.05% solution of Protease VIII (Sigma, St Louis) for 3 min at 37ЊC, blocked at room temperature water. They were then treated with uranyl acetate and examined at 80 kV with a transmission electron microscope (1200 EX; JEOL, with normal goat serum for 20 min, and incubated for 1 h with rabbit anti-EBO serum diluted 1:500 with 1% powdered milk in Peabody, MA). All virions and spheres were counted in a total of 100 grid squares, and the virus titer was calculated.
PBS. Sections were incubated for 30 min each with biotinylated goat anti-rabbit IgG (Vector Laboratories, Burlingame, CA) and Serial passage of EBO virus in mice. Newborn litters of BALB/c mice and adult female BALB/c, C57BL/6, and ICR (CDalkaline phosphatase-labeled streptavidin (Life Technologies Gibco BRL, Gaithersburg, MD). Slides were placed in naphthol 1) mice were obtained from the National Cancer Institute, Frederick, MD. Serial passage was initiated by inoculating litters of 2-AS-BI phosphate/hexazotized new fuchsin (Kirkegaard & Perry, Gaithersburg, MD) for color development and counterstained with day-old suckling BALB/c mice ip with EBO-Z '76 Mp3 Vp2. Eight days later, the litters were killed, and livers and spleens were Mayer's hematoxylin. Necropsy tissues from EBO-infected monkeys served as positive removed aseptically and pooled. They were then ground in a mortar with sterile sand and growth medium, and the suspension was controls. Liver and spleen from uninfected mice and the substitution of normal rabbit serum for rabbit anti-EBO serum served as clarified by low-speed centrifugation and titrated. In passages two through eight, the pooled liver suspension was inoculated subcutanegative controls. Small fragments of tissue for EM were immersion fixed for 1 h in 2% glutaraldehyde in 0.1 M Millonig's phosneously (sc) into new litters, and the process was repeated. Animals were killed 8-10 days after inoculation. Passage 2 was carried phate buffer (pH 7.4), rinsed in buffer, and postfixed for 1-2 h in 1% osmium tetroxide in buffer. The material was then rinsed, out in 2-day-old, passages 3-6 were carried out in 4-day-old, passages 7 and 8 were carried out in 8-day-old, and passage 9 was stained with 0.5% uranyl acetate in ethanol, dehydrated in ethanol and propylene oxide, and embedded in POLY/BED 812 resin carried out in 15-day-old mice. Mice at each passage level were inoculated with .02 mL of undiluted liver suspension, which ranged (Polysciences, Warrington, PA) for sectioning [15] . Neutralization of virus with antiserum. Aliquots of EBO virus in titer from 200 to 5 1 10 6 pfu/mL. Some ninth-passage mice were inoculated sc and some ip.
in growth medium were mixed with serial dilutions of a commercially acquired purified preparation of IgG from horses hyperimPlaque purification. Vero E6 cells were infected with diluted liver suspension from the ninth mouse passage and covered with munized with EBO-Z (equine IgG; Epidbiomed, Novosibirsk, Russia; provided by Peter Jahrling [5, 18, 19] ) and incubated at 34ЊC an agarose overlay. After staining with neutral red, 11 single plaques were removed by pipette, suspended by freeze-thawing for 1 h. water and heated at 60ЊC for 10 min; a 2-mL aliquot was then used for first-strand cDNA synthesis using a Superscript kit (Life Liver suspension from a moribund ninth-passage mouse BALB/c and CD-1 mice did not differ in their susceptibility to the virus. Mouse-adapted virus was lethal for BALB/c mice ranging in age from 5 to 16 weeks. The LD 50 fell within the Results range of 0.025 -.04 Vero E6 pfu (i.e., a dose of 1 pfu was equivalent to Ç30 LD 50 ). Direct counting by EM of virions Serial mouse passage. Non -mouse-adapted viruses EBO-Z '76 Vp2 and EBO-Z '76 Mp3 Vp2 were lethal for many or mixed with a known concentration of microspheres revealed that 1 pfu was equivalent to 25 -30 virions (figure 2). Therefore, all 4-day-old suckling BALB/c mice when inoculated ip or ic, but they did not cause illness in 8-or 15-day-old mice (data 1 LD 50 equaled roughly 1 virion. Titration of a stock of the 1995 strain of EBO-Z virus by EM gave a similar ratio of not shown). Serial passage was therefore begun in young suckling mice. In the first passage, EBO-Z '76 Mp3 Vp2, which virions to plaque-forming units. EBO disease in adult mice. In a series of experiments, had previously been passed 3 times in suckling mice inoculated ic, was injected ip in 2-day-old mice. About 10 3 pfu of virus mice developed ruffled fur, showed progressive slowing of activity, and began to lose weight 3 days after ip injection of in pooled liver suspension recovered from these animals was then injected sc into 2-day-old mice, producing illness (ruffled 1 or 100 pfu (30 or 3000 LD 50 ) of mouse-adapted virus ( figure  3A) . The smaller dose of virus caused a slightly less precipitous fur and diminished activity) or death in several mice before exsanguination of the remaining animals at day 9 after infeconset of disease and weight loss, but the rate of weight loss, once it commenced, was about the same for the 2 doses. A tion. The livers and spleens of these second-passage mice each / 9d50$$se57 07-29-98 10:41:14 jinfa UC: J Infect 10 5 pfu/g (figure 4), roughly 3 1 10 3 to 2 1 10 4 pfu per spleen. Similarly, virus titers in the liver indicated a total of Ç4 1 10 3 to 1.5 1 10 4 pfu/organ (not shown). The combined quantity of virus in each animal's liver and spleen ranged from Ç8 1 10 3 to 3 1 10 4 pfu, a larger quantity than had been inoculated, giving evidence of viral replication. By contrast, the spleens of mice inoculated with mouse-adapted EBO-Z yielded a mean of 6.2 1 10 7 pfu/g, ú1000 times greater than the mean titer of EBO-Z '76 Vp2 or EBO-Z '76 Mp3 Vp2 at the same time point. A comparable disparity in titers was observed in the liver.
Histology, immunohistochemistry, and ultrastructure in liver and spleen. Two days after ip inoculation of 100 pfu (3000 LD 50 ) of mouse-adapted EBO-Z, the liver appeared essentially normal upon routine light microscopy, but EBO virus antigen was detected in sinusoidal lining cells, consistent with Kupffer's cells, by immunohistochemistry (not shown). By day 4, the liver had developed disseminated, often coalescing, foci of hepatocellular vacuolar change, degeneration, and necrosis ( figure 5A ). Hepatocytes and, less frequently, Kupffer's cells contained large (3-15 mm), pleomorphic, acidophilic, cytoplasmic viral inclu- sions. The sinusoids contained necrotic cellular debris and small outbred and BALB/c and C57BL/6 inbred female mice were inoculated intraperitoneally with 100 pfu (3000 LD 50 ) of EBO-Z '76 Mp3 Vp2 Mp9 GH virus and monitored for survival. All mice became ill within 3 -4 days after injection. Further studies with smaller doses of virus showed no difference in susceptibility between CD-1 and BALB/c mice. similar pattern of acute onset of weight loss has been observed in EBO-infected guinea pigs [11] . Averaged over 8 experiments each, the mean time to death of 98 mice inoculated with 30 LD 50 was 6.9 days, and that of 78 mice inoculated with 3000 LD 50 was 5.8 days. In various experiments, a small number of animals bled spontaneously from the orbit, bladder, gastrointestinal tract, or within the abdominal cavity before death. Two mice showed thrombosis of the hepatic portal veins and infarcts in the liver at necropsy. Blood collected in the last 1 -2 days of illness failed to clot, indicating the presence of a coagulation defect, the nature of which has not yet been determined.
To study in vivo viral replication and organ pathology, we inoculated a group of 16-week-old mice ip with 100 pfu (3000 LD 50 ) of mouse-adapted virus; 1 -3 animals were killed each day. Virus titers in the liver and spleen exceeded 10 7 pfu/g on the second day and then increased more slowly, reaching a maximum of ú10 9 pfu/g in both organs of the only surviving mouse on the fifth postinoculation day ( figure 3B ). The mean serum virus titer peaked on the third day at 7.5 1 10 7 pfu/mL. We compared the replication of non -mouse-adapted and mouse-adapted EBO viruses in adult mice by inoculating animals ip with 100 pfu of EBO-Z '76 Vp2, EBO-Z '76 Mp3 Vp2, or EBO-Z '76 Mp3 Vp2 Mp9 GH and killing them 4 numbers of neutrophils and monocytes. Kupffer's cells, sinusoidal endothelial cells, and hepatocytes within and adjacent to areas of hepatocellular degeneration and necrosis were immunoreactive for EBO virus antigen (figure 5B).
Antigen was also present in circulating monocytes (not shown). Cell-free and cellular debris -associated immunoreactive material was present in the sinusoids. Characteristic EBO virus inclusions and budding virions were observed in hepatocytes, Kupffer's cells, and sinusoidal endothelial cells by EM ( figure 6 ). Large numbers of free virions were present in the sinusoids and Disse's spaces. In the spleen, EBO virus antigen was detected by immunohistochemistry in numerous large mononuclear cells in marginal zones 2 days after infection ( figure 5C ). Ultrastructural examination showed replicating EBO virus in marginal zone macrophages and in macrophages of the splenic white pulp but not in lymphocytes. Infrequent small deposits of fibrin were observed in the red pulp late in the course of infection.
Neutralization of virus by antiserum. The 50% plaque-reduction neutralization titer of equine IgG against mouse- adapted virus with equine IgG blocked its lethality for mice. / 9d50$$se57 07-29-98 10:41:14 jinfa UC: J Infect passage, EZ '76 Mp3 Vp2, and of the mouse-adapted virus, EZ '76 Mp3 Vp2 Mp9 GH, and compared them to the GenBank sequence of the GP gene of the Mayinga strain of EBO-Z virus. The starting stock and the mouse-adapted virus differed identically from the GenBank sequence at the following 3 positions, listed with the GenBank nucleotide first: 6232 AúG, 6775 TúC, and 7670 TúC. These nucleotide differences would result in the following amino acid changes, with the amino acid predicted by GenBank sequence listed first: SúP, SúP, and IúT, respectively. The nucleotide sequence of EZ '76 Mp3 Vp2 also differed from the GenBank sequence at the following 3 positions, with the GenBank nucleotide listed first: 6165 AúG, 6909 CúT, and 7212 AúC. The sequence of the mouse-adapted virus was the same as the GenBank sequence at these sites. These 3 nucleotides form the third bases of codons, and the differences are not predicted to result in amino acid changes. dilutions of anti-MBG serum or normal serum failed to protect against lethal infection (figure 7). Immunization and challenge. Adult mice inoculated ip with 100 pfu of EBO-Z '76 Vp2 or with doses of 1 -1000 pfu of EBO-Z '95 Vp3 showed no visible illness. When challenged ip 3 weeks later with 100 pfu (3000 LD 50 ) of mouse-adapted virus, all mice survived without any sign of disease (data not shown). However, mice that were inoculated ip with a quantity of EBO-Z '95 Vp3 equivalent to 100 pfu, which had been inactivated by heat or by gamma irradiation before injection, were not protected against subsequent challenge with the same dose of virus. ip inoculation of MBG virus did not cause visible illness and did not cross-protect against subsequent challenge with mouse-adapted EBO-Z.
Discussion
Mouse-adapted EBO-Z virus caused illness in adult mice only when injected into the peritoneal cavity. sc inoculation of as much as 10 6 pfu of mouse-adapted virus did not cause visible illness or death in adult mice (not shown). In one experiment, lethality for adult mice. A series of experiments confirmed that deposits were observed throughout the red pulp of the spleens of nonhuman primates dying of EBO infection [8] . Despite the the clear plaque agent was EBO virus rather than a contaminant and that EBO virus caused the illness and death of adult mice.
paucity of fibrin deposition, EBO-infected mice showed other signs of coagulation abnormalities, including occasional sponExamination of a suspension of purified mouse-adapted virus by EM showed typical EBO virions. Assay of these particles taneous bleeding from external and internal sites. More detailed findings from a larger time-course study of EBO-Z in mice demonstrated that lethality depended predictably on inoculation of virus: a dose of Ç3 virions (3 LD 50 ) killed 18 of 20 mice, will be presented in a later report. Another notable characteristic of EBO disease in mice is the while one-tenth of that dose caused 2 deaths in 20 mice. Inoculating this suspension into mice resulted in the appearance of rapidity of virus proliferation. Mouse-adapted EBO-Z replicated in the liver and spleen to titers ú10 8 pfu/g within 3 characteristic replicating EBO virus in the liver and spleen. The virus titer in these organs reached 10 8 pfu/g by the third days after infection, eventually reaching 10 9 pfu/g. These titers exceed reported peak concentrations in the liver and spleen of day after inoculation, coinciding with the onset of illness, and continued to increase until death. monkeys (ú10 7 pfu/g) and guinea pigs (ú10 6 pfu/g) [11] . Peak viremia in mice (ú10 7 pfu/mL) was comparable to maximum As further evidence that lethal infection of mice was caused by EBO-Z, we found that the in vitro and in vivo infectivity titers observed in monkeys (10 6 -10 7 pfu/mL) but exceeded those in guinea pigs (ú10 5 pfu/mL) [2, 11, 23] . Virus titers of the virus suspension was neutralized by IgG from horses hyperimmunized against EBO-Z and that mice previously inocwere higher in the spleen than in the liver or serum, as has been observed in guinea pigs [11] . ulated with the 1976 or 1995 strains of EBO-Z virus were protected against challenge with the agent.
An interesting feature of the EBO mouse model is the disparity between the results of ip and peripheral inoculation. The EBO mouse model has highly desirable features for an animal model of an exceptionally virulent human disease. The
The agent was highly infectious when injected ip: the LD 50 equaled a single EBO virion. In contrast, mice injected sc entire course of illness is played out in a week or less: All mice become acutely ill 3 days after infection, similar to the with doses as large as 10 6 pfu of the same virus did not become ill. This phenomenon is not observed in guinea pigs rapid onset of disease in primates, and die 5 -8 days after challenge. The mouse-adapted agent is fatal for BALB/c mice or nonhuman primates, which are susceptible to EBO or MBG virus inoculated sc, im, or ip. On the basis of these other over a broad age range. The use of purified, aliquotted virus and genetically identical mice of the same sex and similar animal models, there is no reason to believe that peripherally inoculated EBO virus simply remains sequestered at the injecage yields virtually uniform results. Such reproducibility will facilitate statistical evaluation of the effect of prophylactic or tion site in mice rather than entering lymphatic vessels and reaching regional lymph nodes. In fact, we found evidence therapeutic interventions.
We initially suspected that the changes in plaque phenotype that virus inoculated sc, id, or im was taken up by or infected (or both) antigen-presenting cells of the MPS system before and virulence that occurred during serial passage resulted from mutations in the GP gene, which is involved in virus binding or after entry into regional lymph nodes, as mice developed a protective immune response and were protected against subto cellular receptors and entry into cells [22] . However, we found that the predicted peptide sequences of the GP of the sequent ip challenge. Viral replication in lymph nodes draining an injection site pre-and postpassage viruses were identical: Although there were 3 nucleotide differences between the GP sequence of the has been observed after sc inoculation of EBO-Z in guinea pigs [11] . However, it appears that either the corresponding starting stock and that of the mouse-adapted virus, none of the differences was predicted to result in an amino acid change. It cells in mice were refractory to virus replication or that an infection that began in regional lymph nodes was rapidly elimithus appears that accelerated replication of the adapted virus in mice resulted from an alteration in events subsequent to nated through immune mechanisms. We have not determined whether systemic dissemination of peripherally inoculated vivirus entry into cells, which was brought about by a change in a viral protein other than GP.
rus takes place. Virions delivered into the peritoneal cavity are distributed A prominent feature of lethal EBO infection in mice is the involvement of multiple cell types, similar to the pattern of very differently from those injected into the soft tissues. Material inoculated ip passes rapidly through peritoneal lymphatic vessels infection in guinea pigs and primates [6 -8, 10, 11, 14] . In the livers, we observed viral replication in Kupffer's cells, and enters the bloodstream; even red blood cells make this transit within minutes after injection [24] . Virions inoculated ip may hepatocytes, and endothelial cells, leading to disseminated, multifocal necrosis, which resembled pathology in other animal thus reach the bloodstream and initially infect MPS cells in the liver and spleen. Mouse-adapted virus clearly infected these models. The spleens of mice, guinea pigs, and primates showed a similar immunohistochemical localization of EBO virus antiorgans soon after ip inoculation, since titers in the liver and spleen already exceed 10 7 pfu/g 2 days after infection. In marked gen in cells of the MPS system. However, we noted few fibrin deposits in the spleens of moribund mice, while fibrin was contrast to the failure of peripherally inoculated virus to cause systemic infection, it appears that the arrival of even a few more prominent in the spleens of guinea pigs, and copious / 9d50$$se57 07-29-98 10:41:14 jinfa UC: J Infect JID 1998; 178 (September) Kristin Spik, and Michelle Young for expert assistance and helpful virions of mouse-adapted EBO-Z in the liver or spleen leads to discussions.
rapid viral proliferation. This may result either from the presence of a permissive host cell or from a weakness in protective immune mechanisms. Alternatively, some virus inoculated ip may
